Menu visibility control

Video

Events

Startup Surgery

Most Recent

News

Top tech stats: Job automation, driverless cars and much more

News

Startup Weekly: Nesta’s £5m prize fund, Digital Catapult and Seedcamp’s VR cohort and much more

Investments

FinTech startup Quantexa lands $3.3m Series A led by Albion Ventures and HSBC

Press Releases

Starling Bank unveils beta as it begins roll out to first customers
VentureFounders surpasses £40m funding mark in 2 years of operation
Software testing leader TestPlant appoints Dr. John Bates as CEO

London-based biotech company Pulmocide raises $30.4m Series B

biotech
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Pulmocide, a biotech firm run by former GlaxoSmithKline scientists, has closed a $30.4m Series B.

The funding, which will be used to further develop its wholly-owned treatments for respiratory syncytial virus (RSV) and pulmonary aspergillosis, came from SV Life Sciences, Johnson & Johnson’s venture capital arm.

The London-based company also drew support from Touchstone Innovations and F-prime, the venture capital arm of Fidelity.

A $30.4m Series B, a £120m AI fund, a Mario Kart hack and more in The Week in Tech

“Respiratory infections are a significant cause of global morbidity and mortality with a high unmet medical need,” said company CEO Garth Rapeport.

“Pulmocide is developing bespoke inhaled medicines to provide effective and safe therapies for the treatment of RSV and pulmonary Aspergillosis. Our approach is to direct the drug to the site of the infection through an inhaler,” he explained.

The funding, the CEO added, will enable the firm to advance two of its ‘novel’ compounds through early clinical development.

“We are delighted by the interest we’ve received in this round and would like to thank our new and existing shareholders for their support and continued commitment to Pulmocide. We look forward to providing further pipeline updates as developments progress with our important programmes,” Rapeport added.

The news comes after the biotech firm secured $17m Series A round from four investors in November 2013.

Enter your e-mail address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

jobs automation top tech stats

Top tech stats: Job automation, driverless cars and much more
posted 3 hours ago

Startup Weekly

Startup Weekly: Nesta’s £5m prize fund, Digital Catapult and Seedcamp’s VR cohort and much more
posted on March 24, 2017

London skyline

FinTech startup Quantexa lands $3.3m Series A led by Albion Ventures and HSBC
posted on March 24, 2017

The North of England

The top tech hubs in the North of England
posted on March 24, 2017

TWIT Emily 23.03.17

A $30.4m Series B, a £120m AI fund, a Mario Kart hack and more in The Week in Tech
posted on March 24, 2017

Tech and banking

How tech is shaking up the world of banking
posted on March 23, 2017